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Abstract 
BACKGROUND: Advanced lung cancer is indicated with rapid disease development. Interleukin 27 (IL-27) is 
regarded as a cytokine with anti-tumour activities.  
AIM: Since, the impact of type of lung cancer on the level of IL-27 in patient’s serum has not yet been 
investigated; current study evaluated the clinical stages according to American Joint Committee on Cancer 
(AJCC) criteria, Tumor-Node-Metastasis (TNM) stage and the lung cancer spread (localized or widespread) and 
it's correlation with serum IL-27. 
MATERIAL AND METHODS: Thirty patients with confirmed histopathological lung cancer and 30 cancer-free 
healthy individuals as the control group were included in the current study. Patients group were assigned to either 
small cell lung cancer group (SCLC) or non-small cell lung cancer (NSCLC) according to the clinical features and 
the results of lung biopsy specimens. Level of IL-27 was quantified with enzyme-linked immunosorbent assay 
(ELISA) test in serum samples. 
RESULTS: A significant increase in serum IL-27 level was noticed in individuals with lung cancer in comparison 
with the control group. The level of serum IL-27 in the NSCL squamous carcinoma (NSCLC-Sc) type was 
significantly greater than in the NSCLC adenocarcinoma (NSCLC-Ad) type, and in both groups, this variable was 
more than the control group. The serum IL-27 content level was greater in stage III versus stage IV. 
CONCLUSION: The current research confirmed the existence of the anti-tumour components in patients with 
NSCLC. IL-27 can be utilised in diagnosis and screening in early stages of lung cancer along with the 
management of patients. Different levels of IL-27 in different types of lung cancers in the current study can lead to 
design more comprehensive studies in the future. 
 
 
 
 
Introduction 
 
Cancer is still a global critical public health 
issue. Lung cancer is one of the most prevalent 
cancer types, leading to almost 18% of all cancer-
related mortality across the world. Most patients show 
a poor prognosis. Therefore, diagnosis of a 
remarkable number of patients happens at advanced 
stages of the disease [1], [2]. In Iran, after car 
accidents and cardiovascular diseases, lung cancer is 
the third leading cause of death [3]. The aetiology of 
lung cancer remains inadequacy explained. The 
pathogenesis of lung cancer, however, is 
multifactorial. Lung cancer is divided into two main 
types: Small cell lung cancer (SCLC) and non-small 
cell lung cancer (NSCLC), which is subdivided into 
NSCLC adenocarcinoma (NSCLC-Ad), NSCL 
squamous carcinoma (NSCLC-Sc), and NSCLC large 
cell carcinoma (NSCLC-LC) [4]. 
NSCLC accounts for nearly 80% of cases, 
with an overall 5-year survival rate of 13% [5], [6]. 
SCLC is an aggressive tumour that is known for it's 
Clinical Science 
_______________________________________________________________________________________________________________________________ 
 
_______________________________________________________________________________________________________________________________ 
2                                                                                                                                                                                                   https://www.id-press.eu/mjms/index 
 
extensive and rapid metastatic dissemination and 
recurrence the following chemotherapy with a poor 
prognosis [7]. Surgery, chemotherapy and 
radiotherapy are the primary treatments for advanced 
NSCLC [8].  
A definitive diagnosis is confirmed by tissue 
sampling that is often carried out by bronchoscopy [9]. 
Delay in diagnosis or treatment of lung cancer results 
in dissemination into the lung through metastasis. 
Early diagnosis of cancers, especially lung cancer, 
can significantly reduce mortality. Diagnosis of lung 
cancer is difficult in the early stages. Cell and chest 
mucus pathological tests, chest radiography (CTX) 
and CT-scan are some diagnostic methods for lung 
cancer. Non-invasive markers that are cost-effective 
and the new molecular and immunological diagnostic 
methods are crucial in the early stages of the disease 
[10]. 
Accumulating evidence shows that 
inflammation plays an important role in developing of 
the lung cancer, mainly in the induced cases by 
cigarette smoke and other noxious particles and 
gases [11], [12]. Immunoregulatory cytokines may 
play a fundamental role in tumour growth and 
metastases. The association of pro- and anti-
inflammatory cytokines with histology type- or 
smoking-independent lung cancer risk has been 
demonstrated [13], [14]. Interleukin (IL)-27, which is a 
recently discovered member of the IL-12 family of 
cytokines, has been reported to exhibit anti-tumour 
activity in different preclinical test models because of 
anti-angiogenic, antiproliferative, and immune-
enhancing effects [1], [15]. IL-27 is a heterodimer 
cytokine containing the Epstein-Barr virus-induced 
gene 3 (EBI3) and IL-27p28, which engages a 
receptor including gp130 and the IL-27Rα that 
activates activator of transcription (STAT) and Janus 
kinase (JAK)-signal transducer [16]. 
Few studies have been conducted to 
investigate the effect of IL-27 on lung cancers, with 
conflicting results, while most of them have been 
conducted on the mouse or in vitro and few of them 
have been conducted in vivo [17], [18], [19]. Given the 
importance of detecting lung cancer in the early 
stages and imprecision of some available diagnostic 
methods, it will be helpful to find a simple diagnostic 
procedure in which the serum is used. 
In this regard, due to the non-toxicity of IL-27 
in previous clinical studies and the discovery of its 
anticancer properties in other examined tumours [20], 
the present study investigated the use of IL-27 as an 
approach to the diagnosis of lung cancer. This study 
is also the first one to examine the association 
between IL-27 concentration and lung cancer 
according to the type of tumour. The concentration of 
IL-27 in various stages of lung tumour will also be 
investigated. The association between IL-27 in the 
circulatory system and lung cancer can be helpful in 
screening, evaluating and treating patients with 
pulmonary involvement symptoms. 
 
 
Material and Methods 
 
In this study, from September 2018 to 
September 2019, inclusion criteria were suffering from 
lung cancer with unknown causes and the age of over 
18 years.  
Definitive diagnosis of lung cancer for the 
referred patients was made based on clinical findings, 
the diagnosis made by an oncologist, and also 
histopathological examination on biopsy or tissue 
samples removed in lung surgery. Individuals with 
inflammatory or infectious diseases were excluded 
from the study. In the control group, individuals with a 
history of autoimmune or malignant disorders and 
those with a family history of lung cancer were not 
included in the study. 
The sample size was calculated by using a 
cross-sectional study sample size calculation formula 
(Standard effect size = 1.1, α = 5%, β = 20%, and 
confidence interval = 95%). Then, 30 patients with 
lung cancer and 30 healthy non-cancer patients, as a 
control group [21], were selected by convenience 
sampling. The participants of the two groups were 
selected in a way that they were matched by age and 
sex. 
The study protocol was confirmed at the 
Ethics Committee. After obtaining written consent to 
participate from the participants, demographic data 
were collected. Before treatment, 4 ml of complete 
venous blood samples of patients were collected in 
anticoagulant free tubes. In the laboratory, a serum 
sample was prepared and stored in a refrigerator at -
20°C. The serum level of IL-27 of the samples isolated 
by enzyme-linked immunosorbent assay was 
evaluated using a kit (R & D Co.). 
Patients, who were enrolled in the study, were 
diagnosed as either NSCLC or SCLC according to the 
results of their clinical specimens and a sample of 
lung biopsy. Clinical stages of patients were 
performed according to American Joint Committee on 
Cancer (AJCC) criteria, Tumor-Node-Metastasis 
(TNM) stage and the disease spread (localised or 
widespread) [22]. 
Data were statistically analysed by Statistical 
Package for Social Sciences (SPSS) (ver. 22.0; SPSS 
Inc. Chicago, IL, USA) software. Statistical analyses 
were conducted following international statistical 
standards. Continuous variables were expressed as 
mean ± standard deviation. Differences between two 
groups were analysed using the Mann – Whitney test 
for continuous variables. A p-value of < 0.05 was 
considered to be statistically significant. 
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Results 
 
In this study, 30 patients with lung cancer 
were studied to investigate the relationship between 
cytokine IL-27 and lung cancer. 13 lung cancer 
patients had NSCL squamous carcinoma, and 11 had 
NSCLC adenocarcinoma (Figure 1).  
 
Figure 1: IL-27 values in lung cancer patients according to TNM 
classification. Bars express mean IL-27 value ± SD, pg/ml 
 
An increase in serum IL-27 level was 
observed in patients with lung cancer in comparison 
with the control group with the Mann Whitney test. 
This study showed that the serum level of IL-27 in 
NSCLC-Sc type was higher than that in NSCLC-Ad 
type (P < 0.05). There was a significant difference 
between IL-27 level in control groups, NSCLC-Ad, and 
Sc-NSCLC (P < 0.05). There was also a significant 
difference between NSCLC-Ad group and NSCLC-Sc 
group (P < 0.05) regarding IL-27 level.  
As illustrated in Figure 2, serum IL-27 levels 
are higher in the squamous cell carcinoma group than 
in the adenocarcinoma groups, and also are higher in 
both groups than in the control group.  
 
Figure 2: Serum level of Interleukin-27 in patients with lung cancer 
in comparison with the control group (p < 0.05, Mann-Whitney test) 
In the next step, the IL-27 levels in the two 
groups were examined with the Mann-Whitney test 
according to different stages of the disease. Patients 
with III clinical stage showed a higher IL- 27 level in 
comparison with patients with clinical stage IV (Figure 
3).  
 
Figure 3: IL-27 levels of lung cancer patients classified according to 
the AJCC. Values are expressed as mean ± SEM; *p < 0.05; **p < 
0.01; c–controls 
 
 
Discussion 
 
Several studies have recently suggested the 
role of IL-27 polymorphisms in the risk of developing 
different types of cancer such as nasopharyngeal 
carcinoma, hepatocellular carcinoma, oesophagal 
cancer, ovarian cancer, cervical cancer, and glioma 
with conﬂicting results [15], [23] but its role in lung 
cancer has not yet been studied. In this study, 30 
patients with lung cancer and 30 healthy individuals 
participated. The primary aim of this study was to 
investigate the serum level of IL-27 in these two 
groups. The current study showed that the overall 
level of IL-27, irrespective of the type of cancer, was 
higher in patients with lung cancer than in the control 
group. NSCLC-Sc was the most frequent type of lung 
cancer among the samples. This type of lung cancer 
seems to have a higher prevalence in society so that 
in a study in China, most patients with NSCLC had 
squamous cell carcinoma (58.2%), and the rest were 
found to have adenocarcinoma (41.8%) [1], which is 
consistent with the present study. 
It has recently been found that IL-27 produces 
strong antitumor effects against different tumour 
models through a variety of mechanisms in various 
cancer cell lines and in vitro, not only by exerting 
direct effects on the tumor cells but also by activating 
anti-tumor immune responses [20], including IL-27 
antitumor, anti-inflammatory and antiangiogenic 
effects-mediated activities and activation of natural 
killer (NK) cells antimetastatic activities [21]. 
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IL-27 antitumor components were also 
observed in lung cancer in another study. IL-27 seems 
to increase IFN-γ production that is necessary to 
differentiate TH0 to T-helper-1 (Th1) cells and induce 
cellular immune system [22]. 
Another aim of the present study was to 
investigate the level of IL-27 in various stages of lung 
cancer. In this regard, an increase in serum IL-27 
level was observed in stage III of the disease 
compared to stage IV. This could indicate the 
importance of a tumour being concentrated in a part of 
the lung and metastasis has not been developed. In 
previous studies, it was also found that IL-27 will be 
very high if a pulmonary tumour is small and at the 
earlier stages [19]. 
Naumnik et al. did not observe any 
diﬀerences in IL-27 concentrations between patients 
with late-stage lung cancer and controls, and they 
also noted an insignificant increase in IL-27 in serum 
samples of patients of stage IIIB compared to those of 
stage IV [17]. Barrera et al. studied the association of 
cytokine profile with survival prognosis in serum 
samples of 110 NSCLC patients. Out of the 
investigated cytokines, IL-27 was significantly higher 
in non-smoker patients, the patients of IIIB stage, 
patients without CNS metastases, and those with 
positive pleural effusion [13], which is consistent with 
our study. 
Karlicic et al. found that mean IL-27 
concentration was significantly higher in healthy 
control people than in lung cancer patients and the 
severity of the disease dissemination was significantly 
correlated with IL-27 levels [19]. 
In the current study, IL-27 was indicated as a 
beneficial prognosis parameter in the early diagnosis 
of lung cancer. IL-27 was shown as a beneficial 
indicator in early diagnosis of lung cancer. Several 
previous studies have reported an increased level of 
serum IL-27 in association with several diseases, 
such as Sarcoidosis, allergic alveolitis and mainly 
pulmonary tuberculosis, which is also very life 
threatening and may result in death due to 
hemoptysis. Therefore, it is obligated to differentiate 
lung cancer from other diseases with similar 
manifestations. Tuberculosis and most of lung cancer 
types differ significantly in scientific signs, 
paramedical diagnostic strategies, direct sputum 
smear and the Ziehl–Neelsen stain, chest X-ray, CT 
[5], [7], [9], [10], [23]. 
Another aim of the study was to investigate 
the relationship between the level of IL-27 and the 
type of a lung tumour. To the best of our knowledge, 
this aim has not yet been taken into account in 
previous studies. In this study, examinations of serum 
samples and histopathology examinations of 
damaged tissues showed that the level of IL-27 was 
higher in Sc-NSCLC type than in NSCLC-Ad, which 
was not shown before. However, in contrast to the 
results of this study, Duan et al. observed a reduction 
of serum IL-27 concentration in NSCLC patients in 
comparison with the healthy controls [20]. The 
differences in the results can be due to the difference 
in the stage of cancer in the cited studies.  
Also, the important findings of the current 
study and the higher levels of IL-27 in NSCLC-Sc than 
in NSCLC-Ad could be the reason for inconsistencies 
in the results of preceding studies, especially because 
the type of cancer was not addressed in past studies. 
Due to the role of lung cancer in serum IL-27 levels, 
discovered here, current study could be followed by 
greater comprehensive studies with larger sample 
size. However, a combination of different cytokines 
seems to play a role in the development of complex 
anti-inflammatory and anti-tumour properties in lung 
cancer and determine the prognosis of the disease.  
In conclusion, the current study suggests that 
IL-27 can be used as an early diagnostic and 
screening tool for lung cancer. IL-27 seems to be a 
good indicator of for treatment response in lung 
cancer patients. In the current study, the differences in 
the level of IL-27 in different types of lung cancer was 
observed for the first time, which could be the basis 
for designing more comprehensive studies with larger 
sample sizes. 
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